Proteins from the DNA Damage Response: Regulation, Dysfunction, and Anticancer Strategies

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Aug 7

PMID 34359720

Citations 19

Authors

Caroline Molinaro

Alain Martoriati

Katia Cailliau

Affiliations

Soon will be listed here.

Abstract

Cells respond to genotoxic stress through a series of complex protein pathways called DNA damage response (DDR). These monitoring mechanisms ensure the maintenance and the transfer of a correct genome to daughter cells through a selection of DNA repair, cell cycle regulation, and programmed cell death processes. Canonical or non-canonical DDRs are highly organized and controlled to play crucial roles in genome stability and diversity. When altered or mutated, the proteins in these complex networks lead to many diseases that share common features, and to tumor formation. In recent years, technological advances have made it possible to benefit from the principles and mechanisms of DDR to target and eliminate cancer cells. These new types of treatments are adapted to the different types of tumor sensitivity and could benefit from a combination of therapies to ensure maximal efficiency.

Citing Articles

Overview of Wnt/β-Catenin Pathway and DNA Damage/Repair in Cancer.

Nadin S, Cuello-Carrion F, Cayado-Gutierrez N, Fanelli M Biology (Basel). 2025; 14(2).

PMID: 40001953 PMC: 11851563. DOI: 10.3390/biology14020185.

Ruthenium(II) Complex with 1-Hydroxy-9,10-Anthraquinone Inhibits Cell Cycle Progression at G0/G1 and Induces Apoptosis in Melanoma Cells.

Dias J, Ferreira-Silva G, Viana R, de Araujo Neto J, Ellena J, Correa R Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861126 PMC: 11768811. DOI: 10.3390/ph18010063.

Oleanolic Acid Modulates DNA Damage Response to Camptothecin Increasing Cancer Cell Death.

Mazzarotti G, Cuomo M, Ragosta M, Russo A, DAngelo M, Medugno A Int J Mol Sci. 2025; 25(24.

PMID: 39769237 PMC: 11676975. DOI: 10.3390/ijms252413475.

Advancements in immunotherapy for colorectal cancer treatment: a comprehensive review of strategies, challenges, and future prospective.

Kaviyarasan V, Das A, Deka D, Saha B, Banerjee A, Sharma N Int J Colorectal Dis. 2024; 40(1):1.

PMID: 39731596 PMC: 11682016. DOI: 10.1007/s00384-024-04790-w.

Circadian rhythms and cancer: implications for timing in therapy.

El-Tanani M, Rabbani S, Ali A, Alfaouri I, Al Nsairat H, Al-Ani I Discov Oncol. 2024; 15(1):767.

PMID: 39692981 PMC: 11655929. DOI: 10.1007/s12672-024-01643-4.

References

Ketley R, Gullerova M . Jack of all trades? The versatility of RNA in DNA double-strand break repair. Essays Biochem. 2020; 64(5):721-735. PMC: 7592198. DOI: 10.1042/EBC20200008. View

Helmrich A, Ballarino M, Tora L . Collisions between replication and transcription complexes cause common fragile site instability at the longest human genes. Mol Cell. 2011; 44(6):966-77. DOI: 10.1016/j.molcel.2011.10.013. View

Doksani Y . The Response to DNA Damage at Telomeric Repeats and Its Consequences for Telomere Function. Genes (Basel). 2019; 10(4). PMC: 6523756. DOI: 10.3390/genes10040318. View

Nogueira A, Fernandes M, Catarino R, Medeiros R . Functions in Homologous Recombination and Its Importance on Genomic Integrity Maintenance and Cancer Therapy. Cancers (Basel). 2019; 11(11). PMC: 6893724. DOI: 10.3390/cancers11111622. View

Fell V, Schild-Poulter C . Ku regulates signaling to DNA damage response pathways through the Ku70 von Willebrand A domain. Mol Cell Biol. 2011; 32(1):76-87. PMC: 3255697. DOI: 10.1128/MCB.05661-11. View

Reyes J, Chen J, Stewart-Ornstein J, Karhohs K, Mock C, Lahav G . Fluctuations in p53 Signaling Allow Escape from Cell-Cycle Arrest. Mol Cell. 2018; 71(4):581-591.e5. PMC: 6282757. DOI: 10.1016/j.molcel.2018.06.031. View

Puri N, Pitman R, Mulnix R, Erickson T, Iness A, Vitali C . Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides. Cancer Lett. 2013; 343(1):14-23. PMC: 5839143. DOI: 10.1016/j.canlet.2013.09.010. View

Militello A, Zielli T, Boggiani D, Michiara M, Naldi N, Bortesi B . Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review. Front Oncol. 2019; 9:759. PMC: 6700293. DOI: 10.3389/fonc.2019.00759. View

Szpechcinski A, Florczuk M, Duk K, Zdral A, Rudzinski S, Bryl M . The expression of circulating miR-504 in plasma is associated with EGFR mutation status in non-small-cell lung carcinoma patients. Cell Mol Life Sci. 2019; 76(18):3641-3656. PMC: 6697756. DOI: 10.1007/s00018-019-03089-2. View

10.

Lemaitre C, Grabarz A, Tsouroula K, Andronov L, Furst A, Pankotai T . Nuclear position dictates DNA repair pathway choice. Genes Dev. 2014; 28(22):2450-63. PMC: 4233239. DOI: 10.1101/gad.248369.114. View

11.

Anindya R, Aygun O, Svejstrup J . Damage-induced ubiquitylation of human RNA polymerase II by the ubiquitin ligase Nedd4, but not Cockayne syndrome proteins or BRCA1. Mol Cell. 2007; 28(3):386-97. DOI: 10.1016/j.molcel.2007.10.008. View

12.

Southgate H, Chen L, Tweddle D, Curtin N . ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms. Cancers (Basel). 2020; 12(5). PMC: 7281288. DOI: 10.3390/cancers12051095. View

13.

Blandino G, Di Agostino S . New therapeutic strategies to treat human cancers expressing mutant p53 proteins. J Exp Clin Cancer Res. 2018; 37(1):30. PMC: 5815234. DOI: 10.1186/s13046-018-0705-7. View

14.

Whittemore K, Vera E, Martinez-Nevado E, Sanpera C, Blasco M . Telomere shortening rate predicts species life span. Proc Natl Acad Sci U S A. 2019; 116(30):15122-15127. PMC: 6660761. DOI: 10.1073/pnas.1902452116. View

15.

Cheng E, Hunt P, Naluai-Cecchini T, Fligner C, Fujimoto V, Pasternack T . Meiotic recombination in human oocytes. PLoS Genet. 2009; 5(9):e1000661. PMC: 2735652. DOI: 10.1371/journal.pgen.1000661. View

16.

Pommier Y, Leo E, Zhang H, Marchand C . DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010; 17(5):421-33. PMC: 7316379. DOI: 10.1016/j.chembiol.2010.04.012. View

17.

Haddach M, Schwaebe M, Michaux J, Nagasawa J, OBrien S, Whitten J . Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics. ACS Med Chem Lett. 2014; 3(7):602-6. PMC: 4025669. DOI: 10.1021/ml300110s. View

18.

Gupta A, Shah K, Oza M, Behl T . Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment. Biomed Pharmacother. 2018; 109:484-492. DOI: 10.1016/j.biopha.2018.10.155. View

19.

Yuan M, Zhao S, Chen R, Wang G, Bie Y, Wu Q . MicroRNA-138 inhibits tumor growth and enhances chemosensitivity in human cervical cancer by targeting H2AX. Exp Ther Med. 2019; 19(1):630-638. PMC: 6909785. DOI: 10.3892/etm.2019.8238. View

20.

Liu C, Li J . O-GlcNAc: A Sweetheart of the Cell Cycle and DNA Damage Response. Front Endocrinol (Lausanne). 2018; 9:415. PMC: 6077185. DOI: 10.3389/fendo.2018.00415. View